BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 23057939)

  • 1. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy.
    Sun W
    J Hematol Oncol; 2012 Oct; 5():63. PubMed ID: 23057939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.
    Fakih M
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):427-38. PubMed ID: 23432698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic Therapy in Colorectal Cancer.
    Mody K; Baldeo C; Bekaii-Saab T
    Cancer J; 2018; 24(4):165-170. PubMed ID: 30119079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
    Chung C; Pherwani N
    Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.
    Pavlidis ET; Pavlidis TE
    World J Gastroenterol; 2013 Aug; 19(31):5051-60. PubMed ID: 23964138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential role of nintedanib in treating colorectal cancer.
    Rossi A; Latiano TP; Parente P; Chiarazzo C; Limosani F; Di Maggio G; Maiello E
    Expert Opin Pharmacother; 2017 Aug; 18(11):1153-1162. PubMed ID: 28649871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aflibercept: A Review in Metastatic Colorectal Cancer.
    Syed YY; McKeage K
    Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
    Seeber A; Gunsilius E; Gastl G; Pircher A
    Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
    Takahashi S
    Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miRNA Targeting Angiogenesis as a Potential Therapeutic Approach in the Treatment of Colorectal Cancers.
    Amerizadeh F; Khazaei M; Maftouh M; Mardani R; Bahrami A
    Curr Pharm Des; 2018; 24(39):4668-4674. PubMed ID: 30636586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approaches in angiogenic targeting for colorectal cancer.
    Prat A; Casado E; Cortés J
    World J Gastroenterol; 2007 Nov; 13(44):5857-66. PubMed ID: 17990351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis in Colorectal Cancer: Antibodies.
    Chan E
    Cancer J; 2016; 22(3):179-81. PubMed ID: 27341595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of tumor angiogenesis as a therapeutic target in colorectal cancer.
    Battaglin F; Puccini A; Intini R; Schirripa M; Ferro A; Bergamo F; Lonardi S; Zagonel V; Lenz HJ; Loupakis F
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):251-266. PubMed ID: 29338550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
    Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept a new target therapy in cancer treatment: a review.
    Ricci V; Ronzoni M; Fabozzi T
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):569-76. PubMed ID: 26224565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
    Papadimitriou M; Papadimitriou CA
    Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
    Collins TS; Hurwitz HI
    Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.